Equity Overview
Price & Market Data
Price: $2.32
Daily Change: +$0.08 / 3.45%
Range: $2.20 - $2.37
Market Cap: $4,104,358
Volume: 59,675
Performance Metrics
1 Week: 12.08%
1 Month: -17.14%
3 Months: -64.50%
6 Months: -73.09%
1 Year: -79.02%
YTD: -62.64%
Company Details
Employees: 53
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.